Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

被引：32

作者：

Speer, Michael E. ^{[1
]}

Fernandes, Caraciolo J. ^{[1
]}

Boron, Marnie ^{[2
]}

Groothuis, Jessie R. ^{[2
]}

机构：

[1] Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA

[2] Medimmune Inc, Gaithersburg, MD 20878 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2008年 / 27卷 / 06期

关键词：

cystic fibrosis; RSV; palivizumab; hospitalization;

D O I：

10.1097/INF.0b013e3181673c15

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received >= 1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.

引用

页码：559 / 561

页数：3

共 50 条

[1] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson, Candice
Chan, Parco
Li, Abby
Paes, Bosco
Lanctot, Krista L.
Mitchell, Ian
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (06) : 1113 - 1118
[2] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Candice Bjornson
Parco Chan
Abby Li
Bosco Paes
Krista L. Lanctôt
Ian Mitchell
European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
[3] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
Bosco Paes
Mahwesh Saleem
Doyoung Kim
Krista L. Lanctôt
Ian Mitchell
European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1561 - 1568
[4] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
Paes, Bosco
Saleem, Mahwesh
Kim, Doyoung
Lanctot, Krista L.
Mitchell, Ian
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (08) : 1561 - 1568
[5] Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations
Bjornson, Candice
Chan, Parco
Li, Abby
Paes, Bosco
Lanctot, Krista
Mitchell, Ian
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[6] Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis
Metz, Jakob
Eber, Ernst
Resch, Bernhard
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (06) : 545 - 548
[7] Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
Calomfirescu-Avramescu, Andreea
Toma, Adrian Ioan
Mehedintu, Claudia
Nastase, Leonard
Dima, Vlad
VACCINES, 2025, 13 (02)
[8] Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab
Chan, Parco
Li, Abby
Paes, Bosco
Abraha, Haben
Mitchell, Ian
Lanctot, Krista L.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (12) : E290 - E297
[9] Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016)
Mitchell, Ian
Wong, S. K.
Paes, B.
Ruff, M.
Bjornson, C.
Li, A.
Lanctot, K. L.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (07) : 1345 - 1352
[10] Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland
Groves, H. E.
Jenkins, L.
Macfarlane, M.
Reid, A.
Lynn, F.
Shields, M. D.
PEDIATRIC PULMONOLOGY, 2016, 51 (04) : 379 - 385

← 1 2 3 4 5 →